Sight Sciences (SGHT) Q1 2026 Earnings Transcript

Sight Sciences reported Q1 revenue of $19.7 million, up 13%, and raised full-year 2026 revenue guidance to $83 million-$89 million from $82 million-$88 million while reaffirming adjusted operating expense guidance. Interventional Dry Eye revenue nearly doubled to $1.4 million and Interventional Glaucoma grew 7% to $18.3 million, with gross margin steady at 86% and net loss narrowing to $13.0 million. The company also reiterated a $55 million patent litigation judgment against Alcon, though no cash has been received and the case remains subject to appeal.

Analysis

The setup is improving because SGHT is finally showing that its two franchises can reinforce each other rather than compete for scarce commercial dollars. The important second-order effect is not just revenue acceleration in dry eye, but that each added TearCare account increases the lifetime value of the glaucoma-installed base by creating a second monetization layer inside the same ophthalmology workflow. That makes the growth model more capital efficient than the market likely assumes, because future dollar growth can come from deeper penetration in existing accounts rather than expensive new-customer acquisition alone.

The litigation outcome is a hidden swing factor. Even if cash is delayed, the upheld damages/royalty structure materially improves downside financing risk and may let management defer any equity need long enough to bridge to a cleaner operating inflection; that matters because the stock is likely still being priced off a ‘dilution overhang’ lens. The bigger implication for ALC is not the one-time damages, but a durable economics reset if 10% royalties persist, which could pressure competitor pricing behavior or product mix over time.

The consensus mistake is probably treating TearCare as a reimbursement story when it is really a workflow adoption story with reimbursement as the unlock. Utilization is early and concentrated, which means the next few quarters should be read through activation velocity, reorder density, and account maturity rather than headline account count. If the company can keep conversion of existing glaucoma centers into dry-eye users, the market may have to re-rate the revenue durability far before broad payer expansion arrives.

Key Decisions for Investors

• Go long SGHT on a 3-6 month horizon; the risk/reward improves if cash burn stays near the recent run-rate and dry-eye utilization continues compounding. Target: 20-30% upside if the market starts underwriting a credible path to cash-flow breakeven; risk: reimbursement expansion stalls and growth reverts to a single-segment story.
• Pair trade: long SGHT / short ALC for 1-2 quarters. The long leg benefits from commercialization and potential litigation monetization; the short leg carries royalty drag and headline risk if appeal odds deteriorate. Best expressed after any SGHT pullback tied to litigation timing noise.
• Buy SGHT calls or call spreads into the next 1-2 earnings prints if options are liquid. The catalyst stack is asymmetric: dry-eye payer adds, OMNI Ultra timing, and utilization reacceleration can all hit within months, while downside is partly buffered by reduced cash-burn optics.
• If already long SGHT, trail a stop below the post-earnings support zone and trim on any sharp move that prices in near-term payer wins. This is a prove-it story, not a full-duration compounder yet.